Prof. Yusuf Yilmaz, M.D., is an esteemed clinical hepatologist specializing in metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD. His research focuses on biochemical biomarkers, elastography (Fibroscan), and targeting liver biopsy for high-risk patients. With a wealth of experience, he has led numerous phase II-III studies as a national coordinator. His comprehensive expertise encompasses the pathophysiological mechanisms and natural history of MASLD, alongside a keen interest in exploring novel therapeutic targets. Hi academic Positions include the following: Associate Professor of Medicine at Marmara University (2012); Director of the Institute of Gastroenterology (2014); Professor of Medicine (2017); President/Rector of Recep Tayyip Erdoğan University (2022); President of the Turkish Fatty Liver Study Group; member of the Turkish Association for the Study of the Liver (TASL); and member of the European Association for the Study of the Liver (EASL), The American Association for the Study of Liver Diseases (AASLD), and the Global NASH Council. He is the author of 150+ peer-reviewed papers, has h-index of 58 (August 2024), and has over 22,000 citations recognized.